Navigation Links
Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Date:8/19/2010

LONDON, Aug. 19 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

Quark is currently conducting a Phase II clinical trial of QPI-1002 for the prevention of acute kidney injury in patients undergoing cardiac surgery and for delayed graft function in kidney transplant patients.  Based on the announcement issued by Quark on 18 August 2010, and under the terms of Silence's agreement with Quark, Silence anticipates that its future milestone payments from this program could potentially exceed $65 million.    

Commenting on today's announcement, Phil Haworth, CEO of Silence, said: "We are delighted that Novartis has chosen to take this development option for QPI-1002.  This serves as further validation of Silence's leading AtuRNAi technology and we look forward to receiving the significant milestones as the development of QPI-1002 continues."

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a libra
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... (PRWEB) November 21, 2014 CannLabs, ... cloud based analytics and scientific testing methodologies relating to ... for a $750,000 line of credit from an existing ... pleased to have secured this commitment from one of ... Officer of CannLabs. “This capital will help accelerate our ...
(Date:11/22/2014)... 21, 2014  The element of surprise has been ... they strike without warning. Until now, epidemiologists had nothing ... viral outbreak, resulting in suboptimal responses to both the ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... removed because virus gene structural changes have been found ...
(Date:11/21/2014)... 2014 Offering a complete line of ... Balance promotion . The Sartorius Entris Balance is the ... accuracy, and easy-to-maintain balance entry level balance. , The ... designed to help customer’s bridge the gap between a ... is very durable. Sartorius is the second biggest balance ...
(Date:11/21/2014)... BlueInGreen, LLC ( BlueInGreen® ) ... and PCI, Inc., leading suppliers of ozone process ... selected to provide a new state-of-the-art ozone system ... Noland Wastewater Treatment. The new ozone disinfection ... gas dissolution technology, Pinnacle Ozone’s industry leading Zenith™ ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Viruses' Advantage of Surprise is Lost 2Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4
... Obstructive ... Sleep Apnea, Advanced ... Employee Productivity; Minimize Litigation Risks, CARLSBAD, Calif., Sept. 5 ... manage was the number,of hours a driver spent behind the wheel. ...
... WEST BRIDGEWATER, Mass., Sept. 5 Pressure,BioSciences, Inc. ... has received,approval to CE Mark the Barocycler NEP2320, ... (PCT) instrument. The,Company also announced that it has ... indicating that the Barocycler NEP2320 has been found ...
... a Proven Leader at Driving Growth, SAN FRANCISCO, ... equity firm that focuses on investments in selected segments,of ... software, today announced the appointment of Michael L. Hurt,to ... Mr. Hurt, CEO,of Altra Industrial Motion (Nasdaq: AIMC ...
Cached Biology Technology:Time For the Trucking and Heavy Machinery Industries to Wake Up! 2Time For the Trucking and Heavy Machinery Industries to Wake Up! 3Time For the Trucking and Heavy Machinery Industries to Wake Up! 4Time For the Trucking and Heavy Machinery Industries to Wake Up! 5Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 3Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 4Genstar Names Michael Hurt to Its Strategic Advisory Board 2
(Date:11/5/2014)... Santamaria, associate professor of biology in the UTSA ... in the nation selected to receive a two-year ... for Exploratory Research (EAGER). The funding supports President ... researchers to create new technology that will demystify ... complex behaviors in neuroscience are broken into the ...
(Date:11/4/2014)... at the right time might actually help boost a ... help in understanding animal populations, pest control and managing ... the journal Trends in Ecology and Evolution , ... the kind of positive population effect an overall species ... on the size and developmental stage of the creatures ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... "mother of thousands" (Kalanchoe diagremontiana) makes the tiny plantlets that ... ability to make viable seeds, the plant has shifted some ... Neelima Sinha, professor of plant biology at UC Davis. ... that can grow into new plants. But mother of thousands ...
... Integrating silicon microchip technology with a network of tiny ... at The Johns Hopkins University have developed a thumb-size ... In a recent edition of the journal IEEE Transactions ... reported that they had successfully used the micro-incubator to ...
... to be penetrated by metastasizing cancer cells, so a ... block cancers spread, according to researchers at the ANZAC ... of breast cancer metastasis, the researchers found that a ... cancer to target bone. Dietary calcium, they reason, might ...
Cached Biology News:Thumb-size microsystem enables cell culture and incubation 2Thumb-size microsystem enables cell culture and incubation 3Dietary calcium could possibly prevent the spread of breast cancer to bone 2